BMT CTN Protocol 0401
Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
Below are protocol-related doucments, which may be periodically updated.
- Protocol synopsis, version 8.0 dated September 20, 2010
- Protocol, version 8.0 dated September 20, 2010
- Summary of protocol changes (version 7.0 to 8.0)
- Informed consent, version 8.0 dated September 20, 2010
- Educational Material
- Participating Centers
- This study is posted on clinicaltrials.gov as NCT00329030
- Key Personnel
Protocol Chair: Julie Vose, MD (402-559-3848) jmvose@unmc.edu
Protocol Officer: Marcie Tomblyn, MD (813-745-6284) marcie.tomblyn@moffitt.org
Protocol Coordinator: Roe Wright (301-251-1161) rwright@emmes.com
Medical Monitor: Eneida Nemecek, MD nemeceke@ohsu.edu
This study reached target accrual and closed to patient accrual on July 17, 2009.
